Pubertal development, growth and final height in girls with sexual precocity after therapy with the GnRH analogue D-TRP-6-LHRH. A report on 15 girls, followed after cessation of gonadotrophin suppressive therapy.
Since 1980 15 girls with sexual precocity who were treated with the superactive GnRH-analogue D-TRP-6-LHRH for 1-5 2/12 years were followed for 1 to 5 6/12 years after discontinuation of therapy. Reactivation of puberty became noticeable 2-4 months and growth velocity increased 4-10 months after treatment was stopped. Menarche (or re-mensis) appeared after 3-9 months in 12/15 girls and after 2 6/12 years in 1. At termination of therapy the predicted final height had improved in 6/8 patients. In the 8/15 patients who had reached their final height at the time of study, the achieved final height was practically equal to the post-treatment prediction in 3/8, above it in 4/8 and below it (but equal to the pretreatment prediction) in 1 patients only who was insufficiently treated. It was found that in patients who had started treatment at an earlier bone age, the benefit as concerned final height was greater and was better evaluated by taking into consideration their genetic growth potential.
Kauli
R
R
Institute of Pediatric and Adolescent Endocrinology, Beilinson Medical Center, Petah Tiqva, Israel.
Kornreich
L
L
Laron
Z
Z
D001827:Body Height / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008572:Menarche / Q000187:drug effects; D011627:Puberty / Q000187:drug effects / Q000502:physiology*; D011629:Puberty, Precocious / Q000188:drug therapy / Q000503:physiopathology*; D013997:Time Factors; D017329:Triptorelin Pamoate
D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone